



CoVetLab: working together to strengthen European collaboration on *Mycoplasma bovis* and compare available diagnostic tools

Ridley, Anne; Tardy, Florence; Wisselink, Henk J.; Pelkonen, Sinikka; Lauritsen, Klara Tølbøl; Aspán, Anna

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Ridley, A., Tardy, F., Wisselink, H. J., Pelkonen, S., Lauritsen, K. T., & Aspán, A. (2019). *CoVetLab: working together to strengthen European collaboration on Mycoplasma bovis and compare available diagnostic tools*. Poster session presented at European Mycoplasma Conference 2019, Colindale, London, United Kingdom.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

CoVetLab: working together to strengthen European collaboration on *Mycoplasma bovis* and compare available diagnostic tools


BACKGROUND

Different clinical presentations of disease caused by *Mycoplasma bovis* predominate in European countries with significant economic and welfare impacts. *M. bovis* disease control relies on good husbandry and an early and reliable diagnosis. However, a lack of standardisation of approaches and diagnostic methods applied makes comparison of disease prevalence between countries difficult.

AIMS

- With assistance from CoVetLab.org a consortium of six European national veterinary institutes was established to develop a network of scientists and share tools and expertise on *Mycoplasma bovis*.
- Objectives included hosting workshops and developing ring trials, including collating panels of DNA and serum samples, to evaluate available serological and PCR-based diagnostic tests.

WORKSHOPS



A



B

- A. At Ruokavirasto in Kuopio to develop PCR and ELISA ring trials.
- B. Joint CoVetLab - Nordic Workshop on *M. bovis* in March 2018 at DTU, Lyngby was attended by 45 participants from the veterinary and scientific community from 10 countries.

M. bovis PCR RING TRIAL

- Analytical specificity, sensitivity and comparability of seven different PCR methods used to detect *M. bovis* were assessed.
- All methods were in use by at least one of the participants.
- Five different DNA extraction methods, seven PCRs targeting four different genes and six different real-time PCR platforms.
- One commercial kit, all other PCR assays were in-house tests.




Fig 1.

- Analytical specificity of the PCR methods was comparable, although only PCR-DGGE identified other bovine mycoplasmas.
- Limits of detection varied from 10 to 10³ CFU/ml to 10³ and 10⁶ CFU/ml for real-time and end-point assays, respectively.
- Ct values varied with naturally infected samples, both between laboratories and tests, without affecting interpretation (Fig 1).

M. bovis ELISA RING TRIAL

- Two commercial ELISA systems (ID screen® ELISA (Idvet, Grabels, France) and BIO K302 ELISA (Bio-X Diagnostics, Rochefort, Belgium)) were assessed by inter-laboratory comparison.
- The sample panel (n=180) comprised sera from cattle from five countries with high and low *M. bovis* prevalence.
- Standardised set of samples designed to reflect the range of samples encountered in all partner countries
- Sera were distributed to the six laboratories and tested as recommended by the suppliers of the test kits.
- Inter-laboratory variation associated with transferability of in-house assays precludes meaningful comparisons and so were not included in the analyses.
- Immunoblot enabled statistical evaluation by latent class analysis.

	Informative priors		Uniform priors	
	Median	95% PCI	Median	95% PCI
Sensitivity & specificity				
Sensitivity WB	0.930	[0.889; 0.966]	0.933	[0.887; 0.969]
Specificity WB	0.998	[0.990; 1.00]	0.999	[0.993; 1.00]
Sensitivity ID Screen	0.956	[0.916; 0.990]	0.958	[0.914; 0.994]
Specificity ID Screen	0.993	[0.983; 0.998]	0.994	[0.985; 0.999]
Sensitivity BIO K302	0.488	[0.444; 0.532]	0.488	[0.443; 0.533]
Specificity BIO K302	0.883	[0.854; 0.908]	0.880	[0.851; 0.906]
Covariances				
CoV _{Se} (WB*IDScreen)	0.037	[0.001; 0.071]	0.035	[0.003; 0.072]
CoV _{Sp} (WB*IDScreen)	0.001	[0.000; 0.006]	0.001	[0.000; 0.004]

Fig 2. Assessing sensitivity and specificity of the ELISA and immunoblot tests

- The ID Screen ELISA showed highest agreement with Western blot analysis and performed with higher precision and accuracy than the Bio K302 ELISA (Fig 2).
- The diagnostic sensitivities of the ID Screen® *Mycoplasma bovis* and the Bio K302 ELISA were 95.6 % and 48.8 % respectively, with specificities of 99.3 % and 88.3 %, respectively.

CONCLUSIONS

- This CoVetLab project has enabled scientists from veterinary institutes in Europe undertaking *M. bovis* diagnostics to collaborate on mutually agreed priorities.
- A joint CoVetLab -Nordic Workshop extended opportunities to widen our network of scientists and present preliminary data.
- The comparison of PCR tests has provided reassurance regarding the quality of diagnosis, despite the different target genes and assays used in our laboratories.
- Although only commercial ELISA kits were included, differences in the sensitivity and specificity were obtained.
- Highlights the importance of inter-laboratory studies to assess performance of current and newly available tests.
- References:** [Wisselink et al.](#) "A European interlaboratory trial to evaluate the performance of different PCR methods for *Mycoplasma bovis* diagnosis" accepted **BMC Veterinary Research**.
[Andersson et al.](#) (in preparation).

Anne Ridley¹, Florence Tardy², Henk Wisselink³, Sinikka Pelkonen⁴ , Klara Tølbøl Lauritsen⁵, Anna Aspan⁶ (joint authors)

¹Animal and Plant Health Agency, Department of Bacteriology, Weybridge, United Kingdom.

²Anses Lyon Laboratory, JRU Ruminants Mycoplasmoses, Anses, VetAgro Sup, University of Lyon, France.

³Wageningen Bioveterinary Research, Department of Infection Biology, Lelystad, The Netherlands.

⁴Finnish Food Safety Authority, Ruokavirasto, Research and Laboratory Department, Kuopio, Finland.

⁵National Veterinary Institute Technical University of Denmark, Division of Diagnostics & Scientific Advice, Lyngby, Denmark.

⁶National Veterinary Institute, Department of Microbiology, Uppsala, Sweden.

Anna-Maria Andersson⁶ is acknowledged for her epidemiological analysis of the data